BridgeBio Pharma, Inc. (BIT:1BBIO)

Market Cap	8.04B
Revenue (ttm)	200.79M
Net Income (ttm)	-661.12M
Shares Out	n/a
EPS (ttm)	-3.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112
Average Volume	n/a
Open	37.24
Previous Close	36.20
Day's Range	37.24 - 41.24
52-Week Range	30.18 - 40.61
Beta	n/a
RSI	67.32
Earnings Date	Aug 1, 2025

About Ligand Pharmaceuticals

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 730
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BBIO

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.